nach oben

Acta Diabetologica

Erschienen in:

22.01.2018 | Original Article

The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial

verfasst von: ShadiSadat Seyyedebrahimi, Hadi Khodabandehloo, Ensieh Nasli Esfahani, Reza Meshkani

Erschienen in: Acta Diabetologica | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Aims

Oxidative stress plays a pivotal role in the pathogenesis of type 2 diabetes (T2D). In vitro and animal studies have shown that resveratrol exerts an antioxidant effect, but clinical trials addressing this effect in patients with T2D are limited. The aim of this study was to determine whether resveratrol supplementation affects oxidative stress markers in a randomized, placebo-controlled, double-blind clinical trial.

Methods

A total of 48 patients with T2D randomly were assigned to receive 800 mg/day resveratrol or placebo for 2 months. Plasma total antioxidant capacity, malondialdehyde concentration, protein carbonyl and total thiol contents, intracellular superoxide anion (O₂⁻·) and hydrogen peroxide (H₂O₂) in PBMCs, the expression of genes involved in oxidative stress responses (Nrf2, SOD, Cat, HO-1, RAGE, NOS) in PBMCs, and metabolic and anthropometric parameters were measured at the baseline and at the trial end.

Results

Compared with the placebo group, resveratrol reduced plasma protein carbonyl content and PBMCs O₂⁻· level and significantly increased plasma total antioxidant capacity and total thiol content. Furthermore, the expression of Nrf2 and SOD was significantly increased after resveratrol consumption. Resveratrol had no significant effects on the metabolic and anthropometric parameters except for a significant reduction in weight, BMI, and blood pressure levels. Resveratrol was well tolerated, and no serious adverse event was occurred.

Conclusions

Our study demonstrated that 8 weeks of supplementation with 800 mg/day resveratrol has an antioxidant effect in the blood and PBMCs of patients with T2D.

Clinical Trial Registry number and website IRCT registration number: IRCT2015072523336N1 and http://en.search.irct.ir/view/24752.

Nur mit Berechtigung zugänglich

Brasnyó P, Sümegi B, Winkler G, Wittmann I (2013) Resveratrol and oxidative stress in diabetes mellitus. In: Preedy V (ed) Diabetes: oxidative stress and dietary antioxidants. Elsevier Inc., Amsterdam

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103(2):137–149. https://doi.org/10.1016/j.diabres.2013.11.002 CrossRefPubMed

Ilechukwu C, Ebenebe U, Ubajaka C, Ilika A, Emelumadu O, Nwabueze S (2014) The role of oxidative stress in diabetes mellitus: a 24-year review. Afrimedic J 5(1):1–7

Francisqueti FV, Chiaverini LC, Santos KC et al (1992) The role of oxidative stress on the pathophysiology of metabolic syndrome. Rev Assoc Med Bras 63(1):85–91. https://doi.org/10.1590/1806-9282.63.01.85 CrossRef

Folli F, Corradi D, Fanti P et al (2011) The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro-and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev 7(5):313–324CrossRefPubMed

Tiwari BK, Pandey KB, Abidi A, Rizvi SI (2013) Markers of oxidative stress during diabetes mellitus. J Biomark, Art id 378790

Martín-Gallán P, Carrascosa A, Gussinyé M, Domínguez C (2003) Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 34(12):1563–1574. https://doi.org/10.1016/s0891-5849(03)00185-0 CrossRefPubMed

Timmers S, de Ligt M, Phielix E et al (2016) Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: a randomized controlled trial. Diabetes Care 39(12):2211–2217CrossRefPubMed

Gawlik K, Naskalski J, Fedak D et al. (2015) Markers of antioxidant defense in patients with type 2 diabetes. Oxid Med Cell Longev 2016:2352361

10.

Javkhedkar AA, Quiroz Y, Rodriguez-Iturbe B et al (2015) Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 308(10):R840–R846. https://doi.org/10.1152/ajpregu.00308.2014 CrossRefPubMedPubMedCentral

11.

Jimenez-Osorio AS, Picazo A, Gonzalez-Reyes S, Barrera-Oviedo D, Rodriguez-Arellano ME, Pedraza-Chaverri J (2014) Nrf2 and redox status in prediabetic and diabetic patients. Int J Mol Sci 15(11):20290–20305. https://doi.org/10.3390/ijms151120290 CrossRefPubMedPubMedCentral

12.

Gerszon J, Rodacka A, Puchała M (2014) Antioxidant properties of resveratrol and its protective effects in neurodegenerative diseases. Adv Cell Biol. https://doi.org/10.2478/acb-2014-0006 CrossRef

13.

Smoliga JM, Baur JA, Hausenblas HA (2011) Resveratrol and health—a comprehensive review of human clinical trials. Mol Nutr Food Res 55(8):1129–1141. https://doi.org/10.1002/mnfr.201100143 CrossRefPubMed

14.

Gülçin İ (2010) Antioxidant properties of resveratrol: a structure—activity insight. Innov Food Sci Emerg Technol 11(1):210–218. https://doi.org/10.1016/j.ifset.2009.07.002 CrossRef

15.

de la Lastra CA, Villegas I (2007) Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Portland Press Limited, London

16.

Wood LG, Wark PA, Garg ML (2010) Antioxidant and anti-inflammatory effects of resveratrol in airway disease. Antioxid Redox Signal 13(10):1535–1548CrossRefPubMed

17.

Movahed A, Nabipour I, Lieben Louis X et al (2013) Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Altern Med eCAM 2013:851267. https://doi.org/10.1155/2013/851267 CrossRef

18.

Thazhath SS, Wu T, Bound MJ et al (2016) Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. Am J Clin Nutr 103(1):66–70CrossRefPubMed

19.

Chakraborty A, Chowdhury S, Bhattacharyya M (2011) Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 93(1):56–62CrossRefPubMed

20.

Ghorbani M, Vatannejad A, Khodadadi I, Amiri I, Tavilani H (2016) Protective effects of glutathione supplementation against oxidative stress during cryopreservation of human spermatozoa. Cryoletters 37(1):34–40PubMed

21.

Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R (2003) Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329(1):23–38CrossRefPubMed

22.

Schmatz R, Perreira LB, Stefanello N et al (2012) Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Biochimie 94(2):374–383. https://doi.org/10.1016/j.biochi.2011.08.005 CrossRefPubMed

23.

Soufi FG, Mohammad-nejad D, Ahmadieh H (2012) Resveratrol improves diabetic retinopathy possibly through oxidative stress–nuclear factor κB—apoptosis pathway. Pharmacol Rep 64(6):1505–1514CrossRefPubMed

24.

Mecocci P, Polidori MC (1822) Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta 5:631–638. https://doi.org/10.1016/j.bbadis.2011.10.006 CrossRef

25.

Ndiaye M, Philippe C, Mukhtar H, Ahmad N (2011) The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges. Arch Biochem Biophys 508(2):164–170. https://doi.org/10.1016/j.abb.2010.12.030 CrossRefPubMedPubMedCentral

26.

Shradha B, Sisodia S (2010) Diabetes, dyslipidemia, antioxidant and status of oxidative stress. Intern J Res Ayurveda Pharm 1(1):33–42

27.

Carrizzo A, Forte M, Damato A et al (2013) Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 61:215–226. https://doi.org/10.1016/j.fct.2013.07.021 CrossRefPubMed

28.

Leonard SS, Xia C, Jiang B-H et al (2003) Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun 309(4):1017–1026CrossRefPubMed

29.

Ghanim H, Sia CL, Abuaysheh S et al (2010) An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 95(9):E1–E8. https://doi.org/10.1210/jc.2010-0482 CrossRefPubMedPubMedCentral

30.

De Groote D, Van Belleghem K, Deviere J, Van Brussel W, Mukaneza A, Amininejad L (2012) Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects. Ann Nutr Metab 61(1):15–24. https://doi.org/10.1159/000338634 CrossRefPubMed

31.

Buonocore D, Lazzeretti A, Tocabens P et al (2012) Resveratrol-procyanidin blend: nutraceutical and antiaging efficacy evaluated in a placebocontrolled, double-blind study. Clin Cosmet Investig Dermatol 5:159–165. https://doi.org/10.2147/CCID.S36102 CrossRefPubMedPubMedCentral

32.

Losa G (2003) Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Investig 33(9):818–823CrossRef

33.

Bo S, Ciccone G, Castiglione A et al (2013) Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem 20(10):1323–1331CrossRefPubMed

34.

Imamura H, Yamaguchi T, Nagayama D, Saiki A, Shirai K, Tatsuno I (2017) Resveratrol ameliorates arterial stiffness assessed by cardio-ankle vascular index in patients with type 2 diabetes mellitus. Int Heart J 58(4):577–583CrossRefPubMed

35.

Samsamikor M, Daryani NE, Asl PR, Hekmatdoost A (2016) Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res 47(4):304–309CrossRefPubMed

36.

Bhatt JK, Nanjan MJ (2013) Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. Int Res J Pharm 4(8):245–249. https://doi.org/10.7897/2230-8407.04849 CrossRef

37.

Brasnyo P, Molnar GA, Mohas M et al (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106(3):383–389. https://doi.org/10.1017/S0007114511000316 CrossRefPubMed

38.

Hausenblas HA, Schoulda JA, Smoliga JM (2015) Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus—systematic review and meta-analysis. Mol Nutr Food Res 59(1):147–159. https://doi.org/10.1002/mnfr.201400173 CrossRefPubMed

39.

Sahebkar A (2013) Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 71(12):822–835. https://doi.org/10.1111/nure.12081 CrossRefPubMed

40.

Elgebaly A, Radwan IA, AboElnas MM et al (2017) Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis. J Gastrointest Liver Dis 26(1):59–67. https://doi.org/10.15403/jgld.2014.1121.261.ely CrossRef

41.

Méndez-del Villar M, González-Ortiz M, Martínez-Abundis E, Pérez-Rubio KG, Lizárraga-Valdez R (2014) Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord 12(10):497–501CrossRefPubMed

42.

Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A (2014) Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 34(10):837–843. https://doi.org/10.1016/j.nutres.2014.09.005 CrossRefPubMed

43.

Kim S, Jin Y, Choi Y, Park T (2011) Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol 81(11):1343–1351CrossRefPubMed

44.

Lasa A, Churruca I, Eseberri I, Andrés-Lacueva C, Portillo MP (2012) Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol Nutr Food Res 56(10):1559–1568CrossRefPubMed

45.

Wang S, Liang X, Yang Q et al (2015) Resveratrol induces brown-like adipocyte formation in white fat through activation of AMP-activated protein kinase (AMPK) α1. Int J Obes 39(6):967–976CrossRef

46.

Yang JY, Della-Fera MA, Rayalam S et al (2008) Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci 82(19–20):1032–1039. https://doi.org/10.1016/j.lfs.2008.03.003 CrossRefPubMed

47.

Hu P, Zhao L, Chen J (2015) Physiologically achievable doses of resveratrol enhance 3T3-L1 adipocyte differentiation. Eur J Nutr 54(4):569–579. https://doi.org/10.1007/s00394-014-0738-4 CrossRefPubMed

48.

Lagouge M, Argmann C, Gerhart-Hines Z et al (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127(6):1109–1122. https://doi.org/10.1016/j.cell.2006.11.013 CrossRefPubMed

49.

Christenson J, Whitby SJ, Mellor D et al (2016) The effects of resveratrol supplementation in overweight and obese humans: a systematic review of randomized trials. Metab Syndr Relat Disord 14(7):323–333. https://doi.org/10.1089/met.2016.0035 CrossRefPubMed

50.

Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomas-Barberan FA, Teresa Garcia-Conesa M, Carlos Espin J (2013) Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des 19(34):6064–6093CrossRefPubMedPubMedCentral

51.

Gummesson A, Nyman E, Knutsson M, Karpefors M (2017) Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab 19(9):1295–1305. https://doi.org/10.1111/dom.12971 CrossRefPubMed

52.

Liu Z, Song Y, Zhang X et al (2005) Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharm Physiol 32(12):1049–1054CrossRef

Titel: The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial
verfasst von: ShadiSadat Seyyedebrahimi
Hadi Khodabandehloo
Ensieh Nasli Esfahani
Reza Meshkani
Publikationsdatum: 22.01.2018
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 4/2018
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-017-1098-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation

Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the area of blood glucose and insulin concentrations

Levels of serum uric acid at admission for hypoglycaemia predict 1-year mortality

Bisphenol A is not associated with a 5-year incidence of type 2 diabetes: a prospective nested case–control study

Gestational diabetes and risk of cardiovascular disease up to 25 years after pregnancy: a retrospective cohort study